This HTML5 document contains 69 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q64722054
rdf:type
wikibase:Item
schema:description
klinisch onderzoek կլինիկական փորձարկում clinical trial ensayu clínicu клінічне випробування
rdfs:label
Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery
skos:prefLabel
Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery
schema:name
Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery
p:P1476
wds:Q64722054-F0F3113A-C0A2-4040-BCCF-1E1064392CDE
wdt:P1476
A Randomized Phase II Trial of Temozolomide (TMZ) and Bevacizumab or ABI-007 (ABX)/Carboplatin (CBDCA) and Bevacizumab in Patients With Unresectable Stage IV Malignant Melanoma
p:P582
wds:Q64722054-849182D1-73AA-4B89-8F96-9481E37189E7
wdt:P582
2010-07-01T00:00:00Z
p:P31
wds:Q64722054-08565851-92D1-4E19-98B5-EE80F33404B7
wdt:P31
wd:Q30612
p:P580
wds:Q64722054-9BD3A1F8-3923-4FD9-B342-5A3B24E335C2
wdt:P580
2008-08-01T00:00:00Z
p:P17
wds:Q64722054-C0DCDBE4-8AC2-4FA8-8FE8-2DBD76005F94
wdt:P17
wd:Q30
p:P6153
wds:Q64722054-9358A64E-2865-427F-9F42-C976383C6C5C wds:Q64722054-7970DC0D-0988-4C67-BA5A-C17F6CBB9907 wds:Q64722054-7B2F30FE-562E-4026-B795-4DFE35F2D6C5 wds:Q64722054-447CCFFB-5ED6-43E0-B516-12465A1F6101 wds:Q64722054-5D9794BC-DAB6-4BCC-8418-A4D53B2FBF27 wds:Q64722054-742D4F16-7925-412E-BBAC-E3C6D6ADCD2B wds:Q64722054-38D1651F-C52C-442C-8724-BD85E0CF7F8E wds:Q64722054-3BF6C77B-6336-4934-9436-36C7E0EFD64E wds:Q64722054-43285EBE-E59E-4DB2-9F29-E8203821CD86 wds:Q64722054-211DF578-35CD-4055-A5B8-32F0851F9DB5 wds:Q64722054-2F0AB46C-D128-413B-9AA8-EA3F80C462F5 wds:Q64722054-D1A40BC5-9C29-455E-A40C-54958F54E94D wds:Q64722054-E2D01FFA-199D-42FD-92ED-AAE45075D002 wds:Q64722054-A26EC286-9631-484D-8F7C-BA9A2B6D285C wds:Q64722054-A2854336-A3A4-41E2-ACBE-F5770228AF63 wds:Q64722054-8D842E57-A338-40AC-B2AB-937F8F86468F
wdt:P6153
wd:Q6936903 wd:Q14716149 wd:Q30269543 wd:Q30269547 wd:Q30270451 wd:Q30281210 wd:Q5592136 wd:Q770544 wd:Q87932226 wd:Q30280192 wd:Q777403 wd:Q30280592 wd:Q30269666 wd:Q3145247 wd:Q30281132 wd:Q7654755
p:P4844
wds:Q64722054-A2F0B534-4BE3-40EC-89E0-C92D918E0DA1 wds:Q64722054-BEB88D13-572F-4B7C-9F38-F59041382A29 wds:Q64722054-83E97367-5C33-4296-AEC6-590876040B57
wdt:P4844
wd:Q423762 wd:Q413299 wd:Q415588
p:P2899
wds:Q64722054-C79050E0-06F0-44E7-93A9-59051950BB7B
wdt:P2899
18
p:P1050
wds:Q64722054-C1B327B1-8905-49D4-A987-ACE2A2470188
wdt:P1050
wd:Q180614
p:P1132
wds:Q64722054-3E86B767-9174-47B7-A0DA-E8AB702042F3
wdt:P1132
95
p:P8363
wds:Q64722054-79B6B8C9-39BD-4B56-95AB-9C5DBD9203B3
wdt:P8363
wd:Q78089383
p:P3098
wds:Q64722054-778FA65C-404D-4468-9377-7FAFA697E164
wdt:P3098
NCT00626405
p:P6099
wds:Q64722054-B40E7D41-F72C-441F-95B6-2C720DA1C18C
wdt:P6099
wd:Q42824440